Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Antigenic peptides recognized by T lymphocytes from AIDS viral envelope-immune humans.

Nature. 1988 Aug 25;334(6184):706-8. Unique Identifier : AIDSLINE MED/88318926
Berzofsky JA; Bensussan A; Cease KB; Bourge JF; Cheynier R; Lurhuma Z; Salaun JJ; Gallo RC; Shearer GM; Zagury D; Metabolism Branch, National Cancer Institute, Bethesda, Maryland; 20892.

Abstract: T-lymphocyte immunity is likely to be an important component of the immune defence against the AIDS virus, because helper T cells are necessary for the antibody response as well as the cytotoxic response. We have previously predicted two antigenic sites of the viral envelope protein gp120 likely to be recognized by T lymphocytes, based on their ability to fold as amphipathic helices, and have demonstrated that these are recognized by T cells of mice immunized with gp120 (ref. 1). A peptide corresponding to one of these sites can also be induce immunity in mice to the whole gp120 protein. Because many clinically healthy seropositive blood donors have already lost their T-cell proliferative response to specific antigen, we tested the response to these synthetic peptides of lymphocytes from 14 healthy human volunteers who had been immunized with a recombinant vaccinia virus containing the AIDS viral envelope gene and boosted with a recombinant fragment. Eight of the 14 responded to one peptide, and four to the other peptide, not included in the boost. These antigenic sites recognized by human T cells may be useful components of a vaccine against AIDS. We also found a correlation between boosting with antigen-antibody complexes (compared to free antigen) and higher stimulation indices, suggesting a more effective method of immunization.

Keywords: Acquired Immunodeficiency Syndrome/PREVENTION & CONTROL Antigens/*IMMUNOLOGY Epitopes/IMMUNOLOGY Human HIV/IMMUNOLOGY HLA Antigens/GENETICS/IMMUNOLOGY *Immunization Immunization, Secondary Peptide Fragments/*IMMUNOLOGY Recombinant Proteins/IMMUNOLOGY Retroviridae Proteins/GENETICS/IMMUNOLOGY T-Lymphocytes/*IMMUNOLOGY Vaccines, Synthetic/*IMMUNOLOGY Vaccinia Virus/*IMMUNOLOGY Viral Envelope Proteins/GENETICS/*IMMUNOLOGY JOURNAL ARTICLE

881230
M88C0024

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .